Humalog Solution for Injection contains Insulin Lispro at a concentration of 100 IU/ml, a rapid-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus. Insulin Lispro is structurally modified to provide a faster onset and shorter duration of action compared to regular human insulin, making it suitable for controlling postprandial blood glucose levels. Humalog is indicated for the treatment of type 1 and type 2 diabetes mellitus and can be administered subcutaneously shortly before or immediately after meals to mimic physiological insulin release. It may also be used in insulin pumps for continuous subcutaneous infusion. The rapid absorption profile allows for greater flexibility in meal timing and improved management of blood glucose excursions. Dosage and administration should be individualized based on patient needs, blood glucose monitoring, and metabolic requirements. Caution is advised to avoid hypoglycemia, the most common adverse effect, which may occur if insulin dose, food intake, or physical activity is not properly balanced. Humalog should not be administered intravenously unless specifically indicated. Proper storage and handling are essential to maintain potency. Patients must be educated on injection technique, dose adjustment, and recognition of hypoglycemia symptoms to optimize therapeutic outcomes.